The latest biotech news

News and Trends 9 Jul 2015

Meet Eligo, the Startup which Raised €2M to Redefine Antibiotics using CRISPR

Antibiotic resistance is a public health problem worldwide. According to WHO, by 2050, over 10 million people will die every year. Microbiomics is a fast evolving field which could play an important role in fighting these resistant bacteria. And CRISPR is literally seen as the biggest Biotech discovery of this century. So, here’s a crazy thought… what would […]

July 9, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 8 Jul 2015

First Success for Imperial Innovations’ Gene Therapy in Cystic Fibrosis

Good news for patients suffering from cystic fibrosis! Imperial Innovations‘ patented gene therapy could improve the patients’ breathing provoking any side effects. An innovation that could help fulfill this unmet medical need. Cystic fibrosis is the most common deadly genetic disease in Europe. Gene deficiency leads to thickening mucus that obstructs lungs and results in […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 Jul 2015

Genmab and Novartis look for the European approval of their leukemia candidate

Genmab is seeking the European authorization for Arzerra, a treatment co-developed with Novartis. The submission is based on the candidate’s positive results in its Phase III in patients with leukemia. Arzerra, the commercial name for ofatumumab, is a human monoclonal antibody that directs the body’s immune system to fight normal and cancerous B-lymphocytes. The drug […]

July 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Jul 2015

CureVac’s mRNA Therapy is Working Against Prostate Cancer

mRNA based immunotherapies are no pipe dream anymore. Germany’s CureVac just presented encouraging results of its Phase IIa clinical study. The firm’s lead mRNA candidate CV9103 is well tolerated and immunogenic in patients with prostate cancer. Based on the favorable data, CureVac initiated a Phase IIb study with a follower prostate cancer vaccine. Just recently, […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Jul 2015

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

Novo Nordisk cancels its collaboration deal with Zosano Pharma. The diabetes drug semaglutine won’t be delivered with the microneedle patch technology, developed from the latter. Zosano’s patch technology uses thin titanium microprojections to deliver drugs that cannot permeate the outer layer of the skin. According to Zosano, the system was tested on 400 patients in […]

July 7, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Jul 2015

DIY-Morphine is around the corner with recent Discoveries in Poppies

Bioproduction of future painkillers such as morphine could become a reality. Researchers from the University of York and GlaxoSmithKline Australia made crucial genetic discoveries in the morphinan synthesis pathway, which will allow its production in microbial systems or in genetically selected plant breeds. Opioid alkaloids have been used as painkillers since the dawn of time. The opium latex is […]

July 7, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 Jul 2015

Microalgae on Your Plate Thanks to Algama

Nine billion people will have to be fed by 2050! Amongst the considered solutions, microalgae could be a real game-changer. Algama, a young French startup is in the starting-block, with already two products just about to go on the market. Behind Algama there is a friendship story, shared by the three co-founders, Alvyn, Gaëtan and Mathieu. […]

July 7, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 6 Jul 2015

Sartorius Stedim Strengthens its Leadership in Biologics Manufacturing with Cellca’s Acquisition

Sartorius Stedim Biotech, a leading international supplier for the pharma and biotech industries, acquired the German-based Cellca last Wednesday. With this acquisition, Sartorius is strengthening its leading position as a biologics manufacturer. Last year, we visited Cellca during our first biotech Tour in Germany. The company is offering cell line and process development for large-scale protein production […]

July 6, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 6 Jul 2015

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

French ElsaLys Biotech just acquired MABLife’s anti-CD160 antibody. Originally developed for the treatment of vascular eye diseases, the antibody also has the potential to be applied for tumor therapy. It inhibits vascular proliferation and modulates the immune system. To proliferate and migrate through the body, tumors rely on oxygen and nutrients supplies. Cancer cells initiate […]

July 6, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Jul 2015

Kiadis launches its Cell-based Immunotherapies on European stock markets

Kiadis Pharma has launched an IPO on Euronext Amsterdam and Euronext Brussels with the aim of raising €32.7M. The company will invest the money in two cell-based immunotherapies for blood cancer and inherited blood disorders. Kiadis has filed for an Initial Public Offering on the Dutch and Belgian exchange markets. The money raised on the […]

July 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Jul 2015

After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO

Two weeks ago, I travelled through Denmark to interview 15 CEOs to film its biotech industry, Labiotech Tour Denmark. Amongst them was Martin Bonde, CEO of Dansk Biotech and former CEO of Epitherapeutics which was sold at €60M to Gilead (the 2nd largest Biotech in the world). I just read he is switching to Vaccibody the Norwegian Biotech and […]

July 6, 2015 - 1 minutemin - By Philip Hemme

News and Trends 5 Jul 2015

CEVEC and Biotest to ease hemophilia patients’ lifes

A German collaboration seeks to treat the symptoms of hemophilia in patients suffering from the later. CEVEC and Biotest will join forces to produce and commercialize molecules using CEVEC’s expression platform. Biotest develops immunoglobulins, coagulation factors and albumins, based on human blood plasma, used for diseases of the immune and hematopoietic system. This makes it […]

July 5, 2015 - 1 minutemin - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Meet Eligo, the Startup which Raised €2M to Redefine Antibiotics using CRISPR

First Success for Imperial Innovations’ Gene Therapy in Cystic Fibrosis

Genmab and Novartis look for the European approval of their leukemia candidate

CureVac’s mRNA Therapy is Working Against Prostate Cancer

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

DIY-Morphine is around the corner with recent Discoveries in Poppies

Microalgae on Your Plate Thanks to Algama

Sartorius Stedim Strengthens its Leadership in Biologics Manufacturing with Cellca’s Acquisition

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

Kiadis launches its Cell-based Immunotherapies on European stock markets

After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO

CEVEC and Biotest to ease hemophilia patients’ lifes

Subscribe to our newsletter to get the latest biotech news!